Plaque psoriasis and psoriatic arthritis: trials to watch in 2022
Four Phase II and III trials in plaque psoriasis or psoriatic arthritis have results expected in 2H 2022, and five Phase III studies have expected completions.
By
Follow @WillNewton19
William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, rare diseases, and the central nervous system. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
Four Phase II and III trials in plaque psoriasis or psoriatic arthritis have results expected in 2H 2022, and five Phase III studies have expected completions.
By William NewtonAs Aristea develops a palmoplantar pustulosis treatment, US and European regulators indicate different primary endpoint preferences.
By William NewtonClinical Trials Arena asks Dr Anthony Fauci about the biggest challenges to selecting long Covid-19 trial endpoints during a…
By William NewtonFour clinical trials in Parkinson’s disease with readouts the second half of 2022 target motor symptom fluctuations and cognitive…
By William NewtonMapping Endpoints: Most clinical trials for pain still use a zero-to-ten scale as a primary endpoint. Experts are on…
By William NewtonThis year’s ASCO meeting highlighted the need to boost diversity in cancer studies. Experts tell Clinical Trials Arena how…
By William NewtonCerevance CMO Jordan Dubow shares exclusive details on the first of two planned registrational trials in Parkinson’s disease.
By William NewtonThere are 100–400 million Dengue fever infections each year, and cases are quickly rising. How can manufacturers overcome obstacles…
By William NewtonIntrommune CEO Michael Nelson details plans for a Phase II trial in children with peanut allergies slated for late…
By William NewtonThank you for subscribing to Clinical Trials Arena